ROVI Pharmaceutical Laboratories
ROVI Pharmaceutical Laboratories is a Spanish pharmaceutical company operating through Specialty Pharmaceuticals (proprietary LMWH Bemiparin and biosimilars) and CDMO contract manufacturing. The publicly-listed Madrid-based company serves healthcare providers and pharmaceutical firms across 60+ countries, with FY2025 revenue of EUR 756 million.
- Company typePublic
- Founded1946
- HeadquartersPozuelo De Alarcón, Spain
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What ROVI Pharmaceutical Laboratories does
ROVI Pharmaceutical Laboratories (Laboratorios Farmacéuticos ROVI, S.A.) is a Spanish pharmaceutical company founded in 1946 and headquartered in Pozuelo de Alarcón, Madrid. The company operates through two primary business units: Specialty Pharmaceuticals, focused on proprietary in-house developed products including Bemiparina (a low molecular weight heparin/LMWH that is ROVI's principal product), biosimilars such as Enoxaparin (targeting a European market exceeding EUR 1,000 million), and prescription and hospital pharmaceuticals; and CDMO (Contract Development and Manufacturing Organization) services providing high-volume contract manufacturing across four plants for prefilled syringes and oral solid forms. The company distributes its LMWH products in 60+ countries through strategic alliances and serves pharmaceutical clients globally through its CDMO business.
ROVI's technology platform centers on proprietary pharmaceutical manufacturing (LMWH production, biosimilar development, prefilled syringes, oral solid forms) and a recently implemented comprehensive digital batch execution system using Rockwell Automation's FactoryTalk PharmaSuite MES, integrated with ROVI's ERP and LIMS platforms. The company monetizes through prescription pharmaceutical sales (Specialty Pharma segment generated EUR 473.9 million in 2025, +2% vs 2023) and contract manufacturing fees (CDMO segment generated EUR 269.5 million in 2025). FY2025 total revenue was EUR 756.1 million (-1% YoY), with EBITDA of EUR 216.2 million (+4% YoY) at a 29.1% margin. R&D spend grew 47% YoY to EUR 37.8 million. Named enterprise customers include Roche (manufacturing collaboration for a new medicine) and potentially Bristol-Myers Squibb (Phoenix site agreement).
ROVI is publicly traded on the Madrid Stock Exchange (ticker: LABFF / bme:ROVI) with 1,001-5,000 employees and offices across Spain, Germany, France, Italy, the UK, and Portugal. The company holds authorized pharmaceutical laboratory status (No. 2808E AEMPS) and is pursuing geographic expansion into North America via the April 2026 closing of a Phoenix, Arizona injectable manufacturing site acquisition from ROIS (announced September 2025, with $50 million minimum annual payments), alongside vertical expansion into AI-assisted diagnostics through majority stakes in SALI Technology and Cells IA Technologies.
ROVI Pharmaceutical Laboratories firmographics
Firmographics- Name
- ROVI Pharmaceutical Laboratories
- Legal name
- Laboratorios Farmacéuticos ROVI, S.A.
- Website
- https://rovi.es
- Company type
- Public
- Founded year
- 1946
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- ROVI Pharmaceutical Laboratories is a Spanish pharmaceutical company operating through Specialty Pharmaceuticals (proprietary LMWH Bemiparin and biosimilars) and CDMO contract manufacturing. The publicly-listed Madrid-based company serves healthcare providers and pharmaceutical firms across 60+ countries, with FY2025 revenue of EUR 756 million.
- Ownership category
- akta.pro rank
ROVI Pharmaceutical Laboratories industry classification
Industry- Product category
- Specialty Pharmaceuticals and CDMO Services
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where ROVI Pharmaceutical Laboratories is headquartered
LocationHeadquarters
- HQ city
- Pozuelo De Alarcón
- HQ country
- Spain
- HQ region
- Europe
Offices8 records
Markets served
ROVI Pharmaceutical Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Specialty Pharmaceuticals: Proprietary pharmaceutical products including low molecular weight heparin (Bemiparin) and biosimilars, sold through prescription pharmaceuticals and hospital products channels.
- CDMO (Contract Development and Manufacturing Organization): Contract manufacturing services for third parties, providing high production capacity with four manufacturing plants for prefilled syringes and oral solid forms.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
ROVI Pharmaceutical Laboratories product offering
Product offeringCore offering
ROVI Pharmaceutical Laboratories researches, develops, manufactures, and markets proprietary pharmaceutical products centered on low molecular weight heparin (Bemiparin) and biosimilars (Enoxaparin), alongside providing contract development and manufacturing (CDMO) services for prefilled syringes and oral solid forms through four manufacturing plants. Its Specialty Pharmaceutical business sells innovative own and licensed products to healthcare providers via prescription and hospital channels across more than 60 countries.
Product overview
ROVI Pharmaceutical Laboratories is a research-focused pharmaceutical company with a diversified portfolio combining proprietary and licensed products. The company's core offerings include Bemiparina (a low molecular weight heparin developed in-house as the principal product), enoxaparin biosimilars, and a broad range of prescription pharmaceuticals and hospital products. ROVI operates across the pharmaceutical value chain through two main segments: Specialty Pharmaceutical business (proprietary products protected by patents) and CDMO services (contract development and manufacturing with four plants for prefilled syringes and oral solid forms). The company maintains global presence in over 60 countries through strategic alliances, with manufacturing capabilities spanning both proprietary products and third-party manufacturing services.
Differentiator
Problem solved
Functional benefit
Brands
- CDMO: Contract manufacturing organization services for prefilled syringes and oral solid forms
- Bemiparina
- Biosimilars
Products and services
- Bemiparina (Low Molecular Weight Heparin) ROVI's principal proprietary low-molecular-weight heparin developed in-house, serving as a key anticoagulant therapy sold through prescription and hospital channels across 60+ countries.
- Enoxaparin Biosimilar Biosimilar version of enoxaparin positioned as a major growth product targeting a European market exceeding EUR 1,000 million.
- Prescription Pharmaceuticals Portfolio Diversified portfolio of innovative proprietary and licensed pharmaceutical products protected by patents, distributed through prescription channels to healthcare providers and hospitals.
- Hospital Products Pharmaceutical products specifically formulated and marketed for hospital use, sold through the hospital products division.
- CDMO (Contract Development and Manufacturing Organization) Services Contract development and manufacturing services for third-party pharmaceutical companies, providing high production capacity across four manufacturing plants for prefilled syringes and oral solid dosage forms.
Companies that use ROVI Pharmaceutical Laboratories
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
ROVI Pharmaceutical Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature3 records
ROVI Pharmaceutical Laboratories partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core, supporting and strategic.
- Rockwell AutomationcoreRockwell Automation collaborated with ROVI to implement a comprehensive digital batch execution system using FactoryTalk PharmaSuite MES. The project, completed in under a year with support from integrator Adasoft, transitioned ROVI from paper-based records to a fully digital environment, connecting ERP and LIMS platforms. Results include improved traceability, reduced review times, and enhanced operational competitiveness. The standardized approach serves as a foundation for future digital rollouts across additional ROVI facilities.
- AdasoftsupportingAdasoft served as the system integrator supporting the implementation of Rockwell Automation's FactoryTalk PharmaSuite MES at ROVI's pharmaceutical manufacturing facilities.
- RochecoreRovi announced a collaboration with Roche for manufacturing a new medicine, representing a strategic partnership for contract manufacturing services.
- ROIScoreRovi acquired a Phoenix-based injectable manufacturing site from ROIS for $50 million minimum annual payments, with a potential Bristol-Myers Squibb manufacturing agreement.
- SALI TechnologystrategicRovi acquired a majority stake in AI-assisted diagnostics company SALI Technology, representing expansion into AI-assisted diagnostics.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
ROVI Pharmaceutical Laboratories competitors and assessment
Company assessmentDirect peers
- Almirall: Spanish specialty pharmaceutical company listed on the Barcelona Stock Exchange with a comparable European focus on prescription and specialty products. Almirall's size, regional footprint, and specialty pharma orientation make it a close structural peer to ROVI.
- Faes Farma: Spanish specialty pharmaceutical company operating in prescription pharmaceuticals, hospital products, and contract manufacturing, with comparable geographic concentration in Spain and Europe. Direct overlap with ROVI in prescription specialty pharma and CDMO-style services.
- Recipharm: European CDMO with prefilled syringe, sterile fill-finish, and oral solid dose capabilities serving global pharma clients. Closely mirrors ROVI's CDMO service offering across dosage forms and customer profile.
- Hovione: Portugal-headquartered CDMO with integrated drug substance and drug product capabilities, including sterile injectables and oral dosage forms. Comparable European footprint and small-molecule CDMO scope to ROVI.
- Siegfried Holding: Swiss-listed CDMO offering API and finished drug product manufacturing including sterile and oral solid dose forms. Comparable scale, European base, and integrated small-molecule CDMO positioning to ROVI.
Broad incumbents
- Sanofi: Global pharmaceutical major whose Lovenox/Clexane (enoxaparin) franchise directly competes with ROVI's Bemiparin (LMWH) and faces the same biosimilar pressure ROVI is targeting with its enoxaparin biosimilar.
- Catalent: Global CDMO leader with deep capabilities in prefilled syringes, biologics fill-finish, and oral solid dose manufacturing. Directly comparable to ROVI's CDMO service line at a larger global scale.
- Lonza Group: Swiss-listed global CDMO leader across small molecules, biologics, and cell & gene services. Overlaps with ROVI's CDMO ambitions, particularly in injectable and small-molecule drug product manufacturing.
- Teva Pharmaceutical: Global specialty and biosimilars major with extensive European presence. Competes with ROVI in biosimilars and specialty pharmaceuticals, including overlapping therapeutic areas such as anticoagulants.
- Pfizer: Global pharmaceutical major whose Fragmin (dalteparin) LMWH franchise competes directly with Bemiparin in the anticoagulant market, and whose contract manufacturing operations overlap with ROVI's CDMO service line.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
ROVI Pharmaceutical Laboratories social profiles
Digital presenceROVI Pharmaceutical Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
ROVI Pharmaceutical Laboratories leadership team
Management profileNumber of profiles
Profiles1 record
ROVI Pharmaceutical Laboratories funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ROVI Pharmaceutical Laboratories M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ROVI Pharmaceutical Laboratories
What does ROVI Pharmaceutical Laboratories do?
ROVI Pharmaceutical Laboratories researches, develops, manufactures, and markets proprietary pharmaceutical products centered on low molecular weight heparin (Bemiparin) and biosimilars (Enoxaparin), alongside providing contract development and manufacturing (CDMO) services for prefilled syringes and oral solid forms through four manufacturing plants. Its Specialty Pharmaceutical business sells innovative own and licensed products to healthcare providers via prescription and hospital channels across more than 60 countries.
Is ROVI Pharmaceutical Laboratories a public or private company?
ROVI Pharmaceutical Laboratories is a public company. It is classified as public and is currently operating.
When was ROVI Pharmaceutical Laboratories founded?
ROVI Pharmaceutical Laboratories was founded in 1946. It employs 1,001 to 5,000 people.
Where is ROVI Pharmaceutical Laboratories based?
ROVI Pharmaceutical Laboratories is headquartered in Pozuelo De Alarcón, Spain, in the Europe region.
How does ROVI Pharmaceutical Laboratories make money?
Two revenue lines are on record. Specialty Pharmaceuticals are the primary driver. The others are CDMO (Contract Development and Manufacturing Organization).
Who are ROVI Pharmaceutical Laboratories's main competitors?
Direct peers on record are Almirall, Faes Farma, Recipharm, Hovione and Siegfried Holding. Broad incumbents are Sanofi, Catalent, Lonza Group, Teva Pharmaceutical and Pfizer.
Does ROVI Pharmaceutical Laboratories have an API?
No public API is recorded for ROVI Pharmaceutical Laboratories.
What industry is ROVI Pharmaceutical Laboratories in?
ROVI Pharmaceutical Laboratories's product category is Specialty Pharmaceuticals and CDMO Services. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.